we've our FTXXX. robust great the Greg. communications Thanks, to has Well, Avadel It's for once-nightly for and the known some team that these set be fully made engaged our here so also broader in rest externalizing the data discuss with data is, are findings how to now community appreciate FTXXX. payer scientific progress can with today medical positive we the fully on time
with our scientific opinion key we have to further expanded Additionally, leaders. team our affairs medical connectivity exchange in
positive Neurology American excited Greg secondary endpoint were month. from mentioned, to of last Academy the these meeting, held two which new data present As There at key XXXX secondary data annual are including. takeaways we was
and light narcolepsy. in in sleep, sleep compared nocturnal is First significant for with in and gram significant X placebo week FTXXX increase sleep decrease X.X evaluated, patients by and time bothersome of demonstrated gram significant three. deep a consolidation frequent all beginning doses of complaint gram, sleep, to living Disturbed X
to daytime middle of from narcolepsy wake night. the REST-ON only most presented that address symptoms, for nighttime supports FTXXX, data without address newly if up narcolepsy in the therapies symptoms approved, this of While once-nightly could sleep having
off Second, commonly significant the both The is well clinical Scale the patient doses and it Sleepiness improvement the as in a Epworth formal when significantly TV, to domains beginning the was all likelihood all Epworth outcome, doses, for of improving Sleepiness which sleep, perceptions as and during patients Epworth activities, FTXXX their as is quality X improved, significantly score. at At three, evaluation, nature a of or refreshing demonstrated FTXXX used the first of dozing light. watching Scale, week evaluates various as ask traffic reduced stopped evaluated. at a patient-reported about such also that practice, in
the of of For from out the approaching score a XX or characteristic narcolepsy, XX normal XX the baseline, with XX, At considered for XX.X, score gram market a dose, indicating also score with not a is week of Epworth below score only a endpoint normal. is context, mean many X of improvement but of of participants.
phase we reminder, trial, compared the previously three the for top X shared to restaurant data evaluated. clinically endpoints, results doses all X.XXX, global all a efficacy met which that of impression improvement, from and as reported FTXXX with were assessed meaningful, As REST-ON placebo three than line have co-primary and weekly less test, statistically mean attacks. These the wakefulness all highly clinical by maintenance p-values pivotal cataplexy significant
to The upcoming of exactly disorders. clinicians With the on appreciate new sleep with month, the at the in more one to FTXXX. AAN, data which can fully dedicated now annual is congress, clinicians results presented totality begin secondary positive endpoint demonstrated commences focused SLEEP
data dissemination to strategy As such, I that am we forward really scheduled. expansive have looking our
engage total a with of in assets, one as These will along action newly housed medical affairs oral be presenting six educational look booth to video created will posters narcolepsy We with virtual of mechanism be specialists. presentation. a we these with our
narcolepsy primary supporting panel how are symposium management of discussion a will we Additionally, an three conveying is which comprised titled, expert evolving, points. be
often is symptoms. daytime manage it nighttime necessary First, and both to
the XX showing treatment release signal And making risk. the sodium and worth oxybate third, for patient's no reviewing of chronic condition. year’s increased of importance data Second, criticality shared cardiovascular of nearly the considering perspective of of this decision immediate
submission our look there publications would of We REST-ON process. on as important to now milestone opinion as providing primary primary this from an numerous manuscript of are publications manuscript, the additional and recently updates publication with in the excellent our forward group trial planned an as in content the key co-authors. you timing the and already to well leaders very reached plans, investigators expect, future. with I and as of Turning
what or suffering FTXXX opinion we their on for mean what a As the that publications, the once-nightly this could working for from in FTXXX, final it provide if will Whether patients from is is really excites takeaway holding key chronic only from our narcolepsy me consistent simply remark, condition. advancement perspective leaders is treatment hear the product. clinical oxybate approved, of a significant advisory as interactions meetings, boards, one-on-one the
update is call Richard, activities. cleaning to hand commercial the floor the Let me now the over on for Richard an yours.
